Curriculum Vitae

|  |  |
| --- | --- |
| Full Name: | *Yan Jin* |
|  |  |
| Position Title: | *Senior Medical Fellow-Clinical Pharmacology* |
|  |  |
| Address: | *5191 Warbler Way South**Carmel, IN 46033* |
|  |  |
| Telephone number: | *(C): 317-625-6311 (H) 317-566-0076* |

**Education:**

|  |  |  |  |
| --- | --- | --- | --- |
| Institution and Location | Degree | Year Conferred | Field of Study |
| Indiana University,Indianapolis, IN 46202 | MS | 2007 | Clinical investigation  |
| Indiana University, School of Medicine, Indianapolis, IN 46202 |  | 2004 | Fellowship in Clinical Pharmacology |
| St. Luke’s HospitalSt. Louis, MO 63017 |  |  1999 | Internal Medicine Residency |
| St. Luke’s HospitalSt. Louis , MO 63017 |  |  1997 | Internal Medicine Internship |
| University of VermontBurlington, VT | MS | 1996 | Nutritional Sciences  |
| Beijing Medical University,School of MedicineBeijing, P.R. China | MD | 1992 | Six year medical program |

Research and Professional Experience:

|  |  |  |
| --- | --- | --- |
| Position | Institution/Employer and Location | Dates of Employment(Month/Year) |
| Sr. Medical Fellow | Eli Lilly and CompanyLilly Corporate Center | Oct 2018 - present |
| Medical Fellow | Eli Lilly and CompanyLilly Corporate Center | Oct 2014-Oct 2018 |
| Senior Medical Advisor | Eli Lilly and CompanyLilly Corporate Center | Oct, 2009-Oct 2014 |
| Clinical Research Physician | Eli Lilly and CompanyLilly Corporate Center | June, 2007-Oct, 2009 |
| Adjunct Assistant Professor of Medicine | Division of Clinical PharmacologyIndiana University , School of MedicineIndianapolis, IN 46202 | June, 2007-Present |
| Associate Clinical Research Physician (Part time) | Eli Lilly and CompanyLilly Corporate Center | Sept. 2004-June. 2007 |
| Assistant professor of Medicine | Division of Clinical Pharmacology Indiana University , School of MedicineIndianapolis, IN 46202 | August 2004-June, 2007 |
| Attending Physician (Internal Medicine) | Women’s Medical Center1650 West Oak Street, Suite 101Zionsville, IN 46077 | December 1999-June 2002 |

Industry experience:

* Represent Eli Lilly and Company at IQ Clinical Pharmacology Leadership Group
* Led the clinical pharmacology team during the FDA and EU submission for a monoclonocal antibody
* Designed and supervised the execution several phase 1 programs in cardiovascular, endocrine and neuroscience therapeutic areas.
* Led the design and implementation of 2 multicenter phase 2 trials
* Chair of protocol review committee for clinical pharmacology and member of internal medicine protocols.
* Member of Immunogenicity Working Group
* Scientific lead for the “DMET haplotype” project that semi-automates the translation of the DMET chip SNP data to CYP star alleles

Academic research focus:

* Clinical pharmacology and pharmacogenetics of breast cancer hormone therapy
* Clinical pharmacology and pharmacogenetics verapamil
* Clinical pharmacology and pharmacogenetics of clopidogrel antiplatelet therapy

Contribution to professional society:

* Member of Membership Action Team of ASCPT
* Reviewer of Clinical Pharmacology and Therapeutics
* Reviewer of British Journal of Clinical Pharmacology

Professional Memberships:

*American Society of Clinical Pharmacology and Therapeutics*

Specialty Board:

Internal Medicine: Board Certified

**Clinical Pharmacology: Board Certified**

Publications

1. C. L. Smith, Y. Jin, E. Raddad, T. A. McNearney, X. Ni, D. Monteith, R. Brown, M. A. Deeg, and T. Schnitzer. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis. *Pharm.Stat.* 18 (1):39-53, 2019.
2. Y. Jin, C. Smith, D. Monteith, R. Brown, A. Camporeale, T. A. McNearney, M. A. Deeg, E. Raddad, N. Xiao, Pena A. de la, A. J. Kivitz, and T. J. Schnitzer. CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial. *Osteoarthritis.Cartilage.* 26 (12):1609-1618, 2018.
3. V. L. Stauffer, R. Sides, M. Lanteri-Minet, W. Kielbasa, Y. Jin, K. J. Selzler, and S. J. Tepper. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. *Patient.Prefer.Adherence.* 12:1785-1795, 2018.
4. Y. Jin, A. Regev, J. Kam, K. Phipps, C. Smith, J. Henck, K. Campanale, L. Hu, D. G. Hall, X. Y. Yang, M. Nakano, T. A. McNearney, J. Uetrecht, and W. Landschulz. Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor. *Br J Clin Pharmacol*, 2017.
5. Y. Jin, C. Smith, L. Hu, D. E. Coutant, K. Whitehurst, K. Phipps, T. A. McNearney, X. Yang, B. Ackermann, T. Pottanat, and W. Landschulz. LY3127760, a Selective Prostaglandin E4 (EP4) Receptor Antagonist, and Celecoxib: A Comparison of Pharmacological Profiles. *Clin Transl.Sci.*, 2017.
6. Y. Jin, C. L. Smith, L. Hu, K. M. Campanale, R. Stoltz, L. G. Huffman, Jr., T. A. McNearney, X. Y. Yang, B. L. Ackermann, R. Dean, A. Regev, and W. Landschulz. Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib. *Clin Pharmacol Ther.* 99 (3):274-284, 2016.
7. Y. Guo, M. W. Farmen, Y. Jin, H. Y. Lee, M. A. Penny, K. M. Hillgren, and S. L. Fossceco. Deciphering ADME genetic data using an automated haplotype approach. *Pharmacogenet.Genomics* 24 (6):292-305, 2014.
8. C. G. Roehrborn, M. E. Spann, S. L. Myers, C. R. Serviss, L. Hu, and Y. Jin. Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. *Prostate Cancer Prostatic Dis*, 2014.
9. R. P. Kreutz, P. Nystrom, Y. Kreutz, J. Miao, R. Kovacs, Z. Desta, D. A. Flockhart, and Y. Jin. Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin. *Platelets.* 24 (2):145-150, 2013.
10. J. D. Duke, X. Han, Z. Wang, A. Subhadarshini, S. D. Karnik, X. Li, S. D. Hall, Y. Jin, J. T. Callaghan, M. J. Overhage, D. A. Flockhart, R. M. Strother, S. K. Quinney, and L. Li. Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. *PLoS.Comput.Biol.* 8 (8):e1002614, 2012.
11. R. P. Kreutz, P. Nystrom, Y. Kreutz, J. Miao, Z. Desta, J. A. Breall, L. Li, C. Chiang, R. Kovacs, D. A. Flockhart, and Y. Jin. Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. *Clin.Pharmacol.* 4:13-20, 2012.
12. J. C. Chappell, G. Dickinson, M. I. Mitchell, H. Haber, Y. Jin, and E. D. Lobo. Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study. *Eur.J Clin Pharmacol*, 2011.
13. S. Borges, Z. Desta, Y. Jin, A. Faouzi, J. D. Robarge, S. Philip, A. Nguyen, V. Stearns, D. Hayes, J. M. Rae, T. C. Skaar, D. A. Flockhart, and L. Li. Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients. *J Clin Pharmacol*, 2010.
14. J. Miao, Y. Jin, R. L. Marunde, S. Kim, S. Quinney, M. Radovich, L. Li, and S. D. Hall. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. *Pharmacogenomics.J* 9 (5):319-326, 2009.
15. J. S. Carpenter, M. Yu, J. Wu, Ah D. Von, J. Milata, J. L. Otte, S. Johns, B. Schneider, A. M. Storniolo, R. Salomon, Z. Desta, D. Cao, Y. Jin, S. Philips, and T. C. Skaar. Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. *Menopause.* 16 (4):644-652, 2009.
16. N. A. Farid, J. A. Jakubowski, C. D. Payne, Y. G. Li, Y. Jin, C. S. Ernest II, K. J. Winters, J. T. Brandt, D. E. Salazar, and D. S. Small. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. *Curr.Med Res.Opin.* 25 (8):1821-1829, 2009.
17. A. A. Onitilo, C. A. McCarty, R. A. Wilke, I. Glurich, J. M. Engel, D. A. Flockhart, A. Nguyen, L. Li, D. Mi, T. C. Skaar, and Y. Jin. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. *Breast Cancer Res Treat.*, 2008.
18. Y. Jin, D. F. Hayes, L. Li, J. D. Robarge, T. C. Skaar, S. Philips, A. Nguyen, A. Schott, J. Hayden, S. Lemler, A. M. Storniolo, D. A. Flockhart, and V. Stearns. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. *J Clin Oncol* 26 (36):5849-5854, 2008.
19. N. I. Ntukidem, A. T. Nguyen, V. Stearns, M. Rehman, A. Schott, T. Skaar, Y. Jin, P. Blanche, L. Li, S. Lemler, J. Hayden, R. M. Krauss, Z. Desta, D. A. Flockhart, and D. F. Hayes. Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen. *Clin Pharmacol Ther* 83 (5):702-710, 8 A.D.
20. Y. Jin, Y. H. Wang, J. Miao, L. Li, R. J. Kovacs, R. Marunde, M. A. Hamman, S. Phillips, J. Hilligoss, and S. D. Hall. Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects. *Clin Pharmacol Ther*, 2007.
21. S. Borges, Z. Desta, L. Li, T. C. Skaar, B. A. Ward, A. Nguyen, Y. Jin, A. M. Storniolo, D. M. Nikoloff, L. Wu, G. Hillman, D. F. Hayes, V. Stearns, and D. A. Flockhart. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. *Clin Pharmacol Ther* 80 (1):61-74, 2006.
22. Y. Jin, Z. Desta, V. Stearns, B. Ward, H. Ho, K. H. Lee, T. Skaar, A. M. Storniolo, L. Li, A. Araba, R. Blanchard, A. Nguyen, L. Ullmer, J. Hayden, S. Lemler, R. M. Weinshilboum, J. M. Rae, D. F. Hayes, and D. A. Flockhart. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. *J Natl Cancer Inst.* 97 (1):30-39, 2005.
23. O. Vitseva, D. A. Flockhart, Y. Jin, S. Varghese, and J. E. Freedman. The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. *J Pharmacol Exp Ther* 312 (3):1144-1150, 2005.